VivaMed partners with medical research universities worldwide to take drug assets from late preclinical development to clinical proof of concept by leveraging strategic partnerships with research scientists, clinicians, CRO's, manufacturers, and scaled life sciences companies. We exit at successful Phase II with commercialization partners who conduct the Phase III pivotal trials required for regulatory approval and market registration. We focus on developing therapeutics for chronic conditions that are resistant to conventional standards of care, such as CNS, Rare Disease, Metabolic, Cardiopulmonary, and Cerebrovascular disorders. We currently have over 50 drug assets under management -- one-third of those are in clinical development.
